Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

30.62
-1.0200-3.22%
Volume:1.37M
Turnover:42.10M
Market Cap:3.69B
PE:-10.11
High:31.77
Open:31.14
Low:30.00
Close:31.64
Loading ...

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

Avidity Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Avidity Biosciences Q4 Basic EPS USD -0.8

THOMSON REUTERS
·
28 Feb

Avidity Biosciences Q4 Operating Expenses USD 123.963 Million

THOMSON REUTERS
·
28 Feb

Circio Holding ASA to Showcase Circular RNA Innovations at Key Biopharma Conferences

TIPRANKS
·
26 Feb

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

GlobeNewswire
·
25 Feb

Arrowhead presents preclinical results on ARO-ALK7

TIPRANKS
·
25 Feb

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Business Wire
·
25 Feb

Maravai Lifesciences Completes Acquisition of Officinae Bio's DNA and RNA Business

MT Newswires Live
·
24 Feb

Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

Business Wire
·
24 Feb

PYC Therapeutics Launches Retail Entitlement Offer to Fund RNA Therapy Development

TIPRANKS
·
24 Feb

BRIEF-Avidity Biosciences Announces Inducement Grants

Reuters
·
22 Feb

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
22 Feb

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
22 Feb

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

GlobeNewswire
·
20 Feb

Avidity Biosciences: Undervalued Entry Point with Promising 2025 Pipeline Despite Market Challenges

TIPRANKS
·
17 Feb

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Simply Wall St.
·
29 Jan

Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies

GlobeNewswire
·
22 Jan

Avidity Biosciences Price Target Maintained With a $67.00/Share by RBC Capital

Dow Jones
·
22 Jan

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan